You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
瑞聯新材(688550.SH):子公司原料藥泊沙康唑通過藥品GMP符合性檢查
格隆匯 06-25 18:22

格隆匯6月25日丨瑞聯新材(688550.SH)公佈,公司的全資子公司渭南瑞聯製藥有限責任公司(以下簡稱"瑞聯製藥")於近日收到陝西省藥品監督管理局簽發的《藥品GMP符合性檢查吿知書》(2024年第24號),瑞聯製藥位於渭南市高新技術產業開發區的生產基地生產的原料藥泊沙康唑(原料藥601生產車間,泊沙康唑生產線)已通過陝西省藥品監督管理局藥品生產質量管理規範符合性檢查(即GMP符合性檢查),結果符合《藥品生產質量管理規範》的要求。

為推動公司醫藥業務從醫藥中間體向原料藥延伸,落實"中間體+原料藥"一體化CMO/CDMO戰略,拓展公司醫藥業務,增強醫藥業務市場競爭力,公司於2021年開始使用超募資金投資建設"渭南瑞聯製藥有限責任公司原料藥項目"。本次通過藥品GMP符合性檢查,表明瑞聯製藥原料藥泊沙康唑符合中華人民共和國《藥品生產質量管理規範》的要求,位於渭南市高新技術開發區崇業路南段的生產基地可以生產上述原料藥產品,標誌着瑞聯製藥已具備原料藥生產能力,為後續其他原料藥產品GMP符合性檢查的申請和原料藥業務的開拓奠定基礎。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account